Barclays Maintains an 'Overweight' on Celgene (CELG); Stumble in Europe, But Expect Continued U.S. Growth

Article Stock Quotes (1) Comments (0)

Barclays maintains an 'Overweight' on Celgene (NASDAQ: CELG) price target of $74.00 (from $83.00).

Analyst, Ying Huang, said, "Withdrawal of European application is disappointing, yet not completely unexpected...We lower our PT to $74, but stock should be supported by floor valuation of $60. Even without front-line maintenance approval in Europe, Revlimid should continue to grow in both the US and Europe on longer duration and higher number of patients."

Barclays lowers FY13 EPS estimate from $5.27 to $4.86.

For an analyst ratings summary and ratings history on Celgene click here. For more ratings news on Celgene click here.

Shares of Celgene closed at $59.45 yesterday, with a 52 week range of $51.70-$80.42.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
• Goldman Sees Blockbuster Potential for Bristol-Myers Squibb's (BMY) Nivolumab (PD-1)
• Supernus (SUPN) PT Trimmed at Jefferies, But Survey Shows Significant Market Opportunity

Create E-mail Alert Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

Barclays

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?